WilmerHale Advises Underwriters in Follow-on Public Offering of Viridian Therapeutics

WilmerHale Advises Underwriters in Follow-on Public Offering of Viridian Therapeutics

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

WilmerHale represented the underwriters in the follow-on public offering of 7,142,858 shares of common stock of Viridian Therapeutics, Inc., a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases. The shares of common stock were issued at a public offering price of $21.00 per share. The gross proceeds to Viridian were $150 million, before deducting underwriting discounts, commissions and offering expenses. The offering priced on January 17, 2024 and closed on January 22, 2024.

The WilmerHale team representing the underwriters consisted of Lisa Firenze, Molly Fox, Katharine Patterson and Milan Kumar, with assistance from Bruce Manheim and Barish Ozdamar.

 

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel